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cDepartment of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, CanadaAbstractPurpose: To compare the complications experienced for 2 different brands of peripherally inserted central venous catheters (PICC), Cook
Turbo-Ject and the Bard PowerPICC Solo2. The rationale for this project revolved around concern that one of the PICCS in question had high
rates of complications.
Methods: A prospective clinical trial was conducted after obtaining approval from the University of Saskatchewan Human Research Ethics
Committee. All PICCs were implanted at the Royal University Hospital Medical Imaging Department by an interventional radiologist.
Patient randomization was achieved by alternating the brand of PICC implanted in sequential patients. All the subjects were inpatients from
a single surgical ward. Patients were excluded from the study if they had a known uncorrected coagulopathy, or if they were being treated for
venous thrombosis. This project was financially supported by the Summer Student Research Fund, College of Medicine, University of
Saskatchewan.
Results: A total of 53 PICCs (25 Bard and 28 Cook) were inserted over the study period. The mean PICC dwell time was 23.3 days for both
the Bard and Cook PICCs, respectively. No statistically significant differences were detected in study group demographics, technical
placement of the PICCs, or in the complications encountered.
Discussion: Both the Cook Turbo-Ject and the Bard PowerPicc Solo2 PICCs provided acceptable venous access for a wide variety of clinical
indications.ResumeObjectif : Comparer les complications observees pour deux marques de catheters centraux inseres par voie peripherique (CCIP), soit le
Turbo-Ject de Cook et le PowerPICC Solo2 de Bard. Le projet avait pour objet de verifier les allegations selon lesquelles un de ces CCIP
presentait des taux superieurs de complications.
Methodes : Un essai clinique prospectif a ete realise apres approbation du Comite d’ethique en recherche sur l’humain de l’Universite de la
Saskatchewan. Tous les CCIP ont ete inseres par un radiologiste specialise en intervention au service d’imagerie medicale du Royal
University Hospital. La randomisation des patients a ete obtenue en alternant la marque de CCIP inseree chez les patients de fac¸on
sequentielle. Tous les sujets etaient des patients hospitalises dans une me^me unite de chirurgie. Les patients qui presentaient une coagu-
lopathie connue non corrigee, ou qui etaient traites pour une thrombose veineuse ont ete exclus de l’etude. Le projet a ete finance par le
Summer Student Research Fund, du College de medecine de l’Universite de la Saskatchewan.
Resultats : Au total, 53 CCIP (25 Bard et 28 Cook) ont ete inseres pendant la periode d’etude. La duree moyenne pendant laquelle les CCIP
ont ete en place etait de 23,3 jours pour les deux marques. Aucune difference statistiquement significative n’a ete decelee concernant les
caracteristiques demographiques du groupe etudie, l’insertion technique des CCIP ou les complications observees.
Discussion : Le Turbo-Ject de Cook et le PowerPicc Solo2 de Bard offrent tous deux un acces veineux acceptable pour un large eventail
d’indications cliniques.
 2012 Canadian Association of Radiologists. All rights reserved.
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gain intravenous (IV) access, which has allowed safe and
effective administration of nutrition, blood products, fluids
and drugs, as well as the ability to withdraw blood samples.
Safe IV access is invaluable to the health care system and is
a vital component to patient care. The development of the
modern IV needles and catheters has a long and complex
history. Much of the impetus for the development of IV
technology revolved around the need for reliable venous
access for the delivery of blood transfusions and fluid
replacement. Although physicians have been experimenting
with IV access for the past 500 years, modern IV access,
therapies, and equipment have only been in practice for
about 25 years [1].
Today, PICCs are used to administer nutrition, blood
products, fluids, or medications (ie, chemotherapy or anti-
biotics). PICCs have gained popularity because they are safe
and effective for patients who require long-term venous
access [2,3]. PICCs have a lower risk of infection and
intraprocedural complications, and overall are less expensive
compared with central venous catheters [4e6]. A compli-
cation of central venous catheters is catheter fracture and
embolization that results from the ‘‘pinch-off syndrome,’’
that is, compression of the catheter between the clavicle and
first rib [5]. The PICC is inserted into a peripheral vein, thus
avoiding the ‘‘pinch-off syndrome’’ [5]. In addition, PICC
design allows for ease of maintenance and can facilitate
patient mobilization and earlier patient discharge.
PICCs have definite advantages, but complications exist.
Early events include catheter-related problems, such as in-
correct tip position; catheter migration; line fracture; and
procedure-related events, such as bleeding and insertion site
trauma [7]. Late events include infection, catheter fracture
and migration, venous thrombosis, and catheter dysfunction
[7]. Catheter occlusion and infection are common compli-
cations, with an incidence of 7%-25% [4e6,8e11].
A wide variety of PICCs are available from various
manufacturers, each designed with unique properties. In this
study, we compared the complication rates of 2 PICC designs
from 2 different vendors: the Cook Turbo-Ject (CookMedical,
Stouffville, ON) and the Bard PowerPICC Solo2 (Bard
Canada Inc, Mississauga, ON). The impetus for this project
centred around the concern that one of the PICCs in question
had an increased rate of complications.
Methods
A prospective clinical trial was conducted at the Royal
University Hospital (RUH) for inpatients from a single
surgical ward, after obtaining approval from the University
of Saskatchewan Ethics in Human Research Board. Informed
consent was obtained from all patients. All PICCs were
placed in the RUH Medical Imaging Department by an
interventional radiologist. Randomization was achieved by
alternating the brand of PICC implanted in the patients. A
patient with a prior PICC was considered a new patient if
he or she required another PICC in the contralateral oripsilateral arm. Patients were excluded from the study if they
had a known uncorrected coagulopathy or if they were being
treated for a known venous thrombosis. Pregnant women also
were excluded.
Patients were followed-up by using a standardized data
collection form. The nursing team on the surgical ward were
involved in the design of the project and agreed to document
PICC-related problems during the study period on the form.
The nurses were not permitted to flush any PICC from which
blood could not be aspirated Therefore, if the nurses were
unable to restore the function of a PICC by replacing the
injection cap, adjusting the PICC dressing, or repositioning
the patient when they could not aspirate blood, then they
were instructed to contact the interventional radiology suite
for an imaging examination of the PICC.
All PICCs that could not be aspirated by the nursing
team were assessed in the interventional radiology suite by
injecting a water-soluble contrast agent during fluoroscopy.
The presence of a fibrin sheath was defined as the accumu-
lation of contrast agent in a confined space that surrounded
the distal tip of the PICC, which restricted the flow of the
injected contrast. The clinical team and the nursing team also
were to report all PICC complications to the interventional
radiology suite for assessment. All PICCs were followed-up
until they were no longer in situ due to the discontinuation of
care or the termination of the PICC related to a complication.
In addition to the prospective data collection, a retrospec-
tive chart review was performed for all study group subjects to
document any clinical or nursing notes that pertained to PICC-
related complications. This project was financially supported
by the Summer Student Research Fund, College of Medicine,
University of Saskatchewan.
PICC Description
The Bard PowerPICC Solo2 is indicated for long-term
(more than 30 days) or short-term (fewer than 30 days)
venous access, IV therapy, power injection of contrast media,
and central venous pressure monitoring. The Bard Power-
PICC Solo was developed in 2007 and was enhanced in 2008
as the Bard PowerPICC Solo2. It is designed with a kink-
resistant polyurethane reversed-tapered design for over-the-
wire placement. It contains 3 internal valves, all located
within the hub. The larger valve is opened by a positive
pressure created by gravity, a pump, or a syringe to allow for
fluid infusion. The 2 smaller valves are opened when a
negative pressure is applied, which allows for blood with-
drawal. The valve system controls the flow of fluids and
provides for a clamp-free strategy. The 2008 improvements
allowed the PICC valves to operate in a wider range of
aspiration pressures, with lower pressures required to open
the valves for aspiration and infusion. Otherwise, the Bard
PowerPICC Solo2 design is the same as the original Bard
PowerPICC Solo. The 5F double-lumen catheter was used
for this study. Both lumens of the PICC were identical in
internal diameter. The maximum power injection rate was
5 mL/s, with a maximum pressure rate of 300 psi.
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PICC intended for short- or long-term use. Indications for
use include venous pressure monitoring, blood withdrawal,
administration of drugs or fluids, and power injection of
contrast and other fluids. The design used for this study was
the 5F double-lumen catheter. Both lumens of the PICC are
identical in internal diameter. The maximum flow rate was
5 mL/s, with a maximum pressure of 325 psi. The Cook
Turbo-Ject PICC has no intrinsic valve technology and each
lumen has an external plastic clamp to control lumen flow.
In addition to the intrinsic valves or the external clamp
technology of the PICCs, an external, needleless valve was
attached to each lumen of the catheter by the ward nursing
team. This was a single lumen, needleless valve (ICU
Medical Inc, San Clemente, CA).
After informed consent was obtained, all PICCs were
implanted by an interventional radiologist in the vascular/
interventional suite by using the aseptic Seldinger technique.
All PICCs were 5F dual-lumen design. All PICCs were
inserted in the same fashion, no unusual techniques were
used for a particular PICC. Each PICC was implanted by
using a peel-away sheath.
The method used for venipuncture was left to the
discretion of the interventional radiologist who was inserting
the PICC by using ultrasound or venography. If the basilic
vein was identified, then it was preferentially used for venous
access. Local anesthesia was administered at the puncture
site by using 1% lidocaine. Venous access was achieved with
a Cook micropuncture set that consisted of a 21-gauge access
needle and a 0.18-inch-diameter, platinum-tipped, guide-
wire (Cook Canada Inc, Mississauga, ON). The needle and
guidewire were replaced with a 6F peel-away sheath. By
using fluoroscopy, a guidewire was positioned in the distal
superior vena cava (SVC). The length of the guidewire was
marked. The PICC was cut to match the guidewire length
(from the skin surface to the distal SVC). The wire was
inserted into the PICC, and the combination was introduced
via the peel-away sheath. The PICC was advanced, by using
fluoroscopy, into the SVC. The guidewire and the peel-away
sheath then were removed. Each catheter lumen was flushed
with sterile saline solution and dead end caps were placed on
each lumen. Both PICCs had suture wings incorporated into
the design of the catheter. The PICCs were affixed to the
patient’s skin by using 2e0 Prolene suture material (Johnson
& Johnson Inc, Markham, ON) in both suture wings of the
catheter. Chest fluoroscopy was used to ensure proper PICC
tip placement at the SVCeright atrial junction. A sterile
dressing was applied at the insertion site. External needleless
valves were placed on each lumen of the PICC when the
patient reached Surgical Ward 5000. All PICCs were
managed identically from the perspective of aspiration,
flushing, and dressing strategies.
Maintenance of PICCs
The nursing team on Surgical Ward 5000 was respon-
sible for the general maintenance of the PICCs. If anycomplications arose, such as those involving blood with-
drawal, or flushing, then vascular/interventional radiology
was contacted for evaluation. The nursing staff was required
to follow a standard flushing and blood withdrawal protocol,
which was identical for both PICCs. Nonheparinized saline
solution was used as the flushing solution for all patients.
The PICC lumen flushing protocol was as follows:
1. Aspirate until blood return into the syringe is achieved
to ensure clearance of the PICC lumen.
2. With a 10-mL syringe, flush the PICC lumen with 10 mL
0.9% NaCl by using the stop-start technique.
The PICC blood withdrawal protocol was as follows:
1. Aspirate until blood return into the syringe is achieved to
ensure clearance of the PICC lumen.
2. Draw 5 mL of blood into same syringe by slowly pulling
and holding the plunger and allowing the valve to open.
Discard the syringe.
3. Attach a Vacutainer (BD Canada, Mississauga, ON) or
syringe and slowly aspirate the blood sample.
4. Flush the PICC lumen with 10 mL of 0.9% NaCl by
using the stop-start technique.
Statistical Analyses
The PICC brand (Bard or Cook) was the independent
variable. PICC complications were the primary dependent
variable. Age, sex, insertion vein, PICC tip position, reason for
PICC insertion, primary and secondary diagnoses, diabetes,
and method of insertion (ultrasound vs fluoroscopy) were
evaluated as potential confounders. Descriptive statistics
were used to summarize data. Means (standard deviations)
were calculated for continuous data, and frequencies were
calculated for categorical data. Between-group comparisons
of categorical data were performed with c2 testing. Two group
comparisons of continuous data were tested with Student t test
(2 tailed). Any analysis that demonstrated a P < .05 was
considered statistically significant. Analysis was carried out
with SAS statistical software version 9.2 (The SAS Institute
Inc, Cary, NC).
Results
A total of 53 PICCs were inserted (Bard, n ¼ 25; Cook,
n ¼ 28). Each variable in patient demographics, technical
placement of the PICC, complications were analysed inde-
pendently for statistical differences. There were no statisti-
cally significant differences for age, sex, diabetes, and primary
or secondary medical diagnosis between the 2 PICC groups
(P > .05) (Table 1). There were no significant differences
detected between the groups regarding method of insertion,
PICC insertion location, tip position, reason for insertion,
or duration of PICC insertion (P> .05) (Table 2). The average
number of days the PICCs were inserted per patient was
23.3 (range, 7-55 days) and 23.3 (range, 2-92 days) for the
Table 1
Patient demographics and disease parameters
Patients
PICC branda
P valueBard (n ¼ 25) Cook (n ¼ 28)
Women 15 (65.2%) 18 (66.7%) .914
Age (y) 56.2  4.7 61.7  3.7 .358
Diabetes
Yes 7 (28%) 5 (17.8%) .331
No 15 (60%) 22 (78.6%)
Unknown 3 (12%) 1 (3.6%)
Primary diagnosis No P value <.346
Neoplastic 4 (18.2%) 11 (42.3%)
Gastrointestinal 8 (36.4%) 7 (26.9%)
Infection 8 (36.4%) 6 (23.1%)
Otherb 2 (9.1%) 2 (7.7%)
Unknown 3 2
n ¼ number of patients; PICC ¼ peripherally inserted central venous
catheter.
a The numbers in parentheses indicate the percentage for each brand
of PICC.
b Includes respiratory (n¼ 1), genitourinary (n¼ 2), and metabolic (n¼ 1).
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catheter days for the Bard PICC was 898 and for the Cook
PICC was 658.
There were no unique complications encountered in
this cohort, all complications encountered were recognized
complications of PICCs that have previously been docu-
mented in the literature. The total number of patients who
experienced complications for both catheter types was 19
of 53 (35.8%), a complication rate of 12.2/1000 catheter
days. There were no statistically significant differences inTable 2
PICC implantation parameters
PICC placementa
PICC brand
P valueBard (n ¼ 25) Cook (n ¼ 28)
Reason for insertion
Total parenteral
nutrition
21 (84.0%) 20 (71.4%) .275
Othersb 4 (16.0%) 8 (28.6%)
Method of insertion
Ultrasound 0 (0.0%) 2 (7.4%) .225
Fluoroscopy 19 (100.0%) 25 (92.6%)
PICC location
Arm
Right 12 (48.0%) 16 (57.1%) .506
Left 13 (52.0%) 12 (42.9%)
Vein
Basilic 22 (88.0%) 20 (71.4%) No P value <.322
Brachial 2 (8.0%) 6 (21.4%)
Cephalic 1 (4.0%) 2 (7.1%)
Tip position
SVC 20 (87.0%) 21 (75.0%) .480
Cavoatrial junction 3 (13.0%) 7 (25.0%)
No. days inserted
(mean  SE)
23.3  3.1 23.3  3.3 .986
n ¼ number of patients; PICC ¼ peripherally inserted central venous
catheter; SE ¼ standard error; SVC ¼ superior vena cava.
a Unavailable data: method of insertion: Bard (n ¼ 6), Cook (n ¼ 1); tip
position: Bard (n ¼ 2).
b Includes antibiotics (n ¼ 2), intravenous access (n ¼ 8), and chemo-
therapy (n ¼ 2).complications between the 2 PICC brands used in the project.
Complications encountered are summarized in Table 3.
There were 12 patients (48%) in the Bard PICC group
who experienced a total of 15 complications, an event rate of
16.7/1000 catheter days. The most common complication
in this group was skin fixation failure, which occurred in
6 cases, for an event rate of 6.7/1000 catheter days. In 4 of
the 6 cases, it was proven that this was the result of the skin
suture working out of the skin anchor point. The second most
common complication in this group was PICC occlusion,
which occurred in 5 instances, all due to fibrin sheath for-
mation. The event rate of fibrin sheath for the Bard PICC was
8.9/1000 catheter days.
There were 7 patients (25%) in the Cook group who
experienced a total of 10 complications, an event rate of 15.2/
1000 catheter days. Skin fixation failure was encountered in 3
cases, an event rate of 4.6/1000 catheter days. In one of these
cases, it was proven that the sutures had worked their way out
of the skin. Occlusion developed in 3 Cook PICCs, 2 of which
were encased by fibrin sheath formation. The event rate of
fibrin sheath formation for the Cook PICC was 3.0/1000
catheter days. The third catheter in this cohort was totally
occluded and had to be removed. It was suspected that 3 of the
Bard PICCS and 3 of the Cook PICCs became infected: event
rates of 3.3/1000 and 4.6/1000 catheter days, respectively. All
of these catheters were removed on the ward, and none
of these cases had cultures performed. One of the subjects in
the Cook group developed central venous thrombosis that
terminated at the axillary-subclavian vein junction. This was
diagnosed by Doppler ultrasound. The event rate for venous
thrombosis was 1.5/1000 catheter days for the Cook PICC.
Discussion
PICCs have gained popularity over central venous cath-
eters because they are safe; easy to insert; effective for
administering nutrition, fluids, or medication; easy to main-
tain and remove; and can be used for prolonged periods of
time. However, PICCs are still challenged, with complica-
tions and the costs associated with the additional care related
to the management of these complications.
In discussing the overall complication rates for patients
with PICCs, it is evident that the rate of complications is
highly variable. A tabulation of PICC complications dem-
onstrates that the percentage of PICCs with complications
varies between 23.2% and 40.7% (6.8-16.7/1,000 catheter
days) [2,4,9,11e15]. The compilation of this previous data is
summarized in Table 4.
Ong et al [12] performed a side-by-side comparison of 2
different PICC brands and found complication rates that
varied between 26.8% and 47.9% [12]. The complication rate
for the Bard group (48%) falls at the upper end of this range,
whereas the Cook group complication rate (25%) was at the
lower end of this range.
Occlusion was one of our most common complications:
5.6/1000 catheter days for the Bard group and 4.6/1000
catheter days for the Cook group. To prevent PICC
Table 3
PICC complications
PICC type Bard (n ¼ 25) Cook (n ¼ 28) P value
Total catheter days 898 658
Patients complications
No 13 (52%) 21 (75%) .506
Yes 12 (48%) 7 (25%)
Both catheters combined 19/53 (35.8%)
Complications experienced n Events/1000 catheter days n Events/1000 catheter days
PICC infection, suspected 3 3.3 3 4.6
PICC occlusion 5 5.6 3 4.6
Skin fixation failure 6 6.7 3 4.6
Migration of PICC tip 1 1.1 0 0
Thrombosis 0 0 1 1.5
Total complications 15 16.7 10 15.2
n ¼ number of patients; PICC ¼ peripherally inserted central venous catheter.
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the line, which prevents blood reflux into the PICC lumen.
To diminish the possibility of occlusion, different manufac-
turers have modified their PICC design, it is hoped, to
prevent blood reflux. Previous studies have proven the
benefit of a valved system in diminishing PICC occlusion
[4,16]. Both Hoffer et al [4] and Hinson and Blough [16]
found statistically significant reductions in catheter occlu-
sion when a valved PICC was deployed. The Cook Turbo-
Ject PICC is designed with external-line clamps, whereas
the Bard PowerPICC Solo2 incorporated an internal valve
system. However, because an external needleless valve was
affixed to both PICCs, the net result was valve protection for
the both PICCs in our study, which prevented any disparity
between the 2 PICC designs.
The most common cause of obstruction in our study
population was fibrin sheath formation, which prevented
aspiration and blood withdrawal; this was the cause for all of
the occlusions in the Bard group and two-thirds of the
occlusions in the Cook group. Fibrin sheath formation is
a complex, multifactorial complication for which there is no
reliable preventative strategy [17,18].
A substantial number of PICCs demonstrated skin fixation
failure, 6 in the Bard group and 3 in the Cook group. Four of
the 6 skin fixation failures in the Bard group were proven toTable 4
Compilation of PICC complications
Study Year No. PICCs
Overall PICC
complication rates
No./1000
catheter days %
Alport et al (current study) 2011 53 12.2 35.8
Ong et al12 2010 392 14.6 37.2
Haider et al2 2009 146 14.4 32.8
Van Winkle et al13 2008 39 16.2 33.3
Cheong et al14 2004 27 12.6 40.7
Walshe et al15 2002 366 10.9 32.8
Hoffer et al4 1999 535 6.8 23.2
Smith et al9 1998 555 16.7 35
Merrell et al11 1994 389 10.2 28.3
PICC ¼ peripherally inserted central venous catheter.be caused by the skin sutures pulling through the skin, which
liberated the PICC from the skin fixation points. This failure
could only be proven to be the cause in one of the subjects in
the Cook group. The Bard PICC seemed to be more rigid in
its construction, and this rigidity may have contributed to
skin fixation failure. All of our subjects were inpatients, and
the severity of their illnesses may have resulted in mobility
and transfer issues that preferentially affected one group
more than the other. The cause of this complication remains
unresolved.
There are a variety of clinical parameters that can alter
complication profiles for medical devices. For instance, it has
been reported that PICC complications can be greater for
oncology patients [2,7,15]. In particular, Haider et al [2]
demonstrated that patients with hematologic malignancies
were more likely to experience complications than those with
solid tumours [2]. Having said this, it should also be noted
that Cheong et al [14] demonstrated that patients with solid
tumours had higher complication rates than patients without
malignancies. Our study population included 18.2% and
42.3% of oncology patients for Bard and Cook groups,
respectively.
All of our subjects were inpatients and often were quite ill
and required a greater degree of nursing care. The mobility
of this group was restricted and required more transfers to
and from their beds. This patient population would certainly
be expected to experience more complications than a mobile
outpatient cohort.
Inpatients have a greater risk of device failure, infection,
and occlusion based upon previous assessment of this patient
population [19,20]. Both of these researchers found that
inpatients had an enhanced risk of complications in general
related to the use of a PICC but also demonstrated that those
inpatients who received IV parenteral nutrition were partic-
ularly at risk for PICC complications. Our patient population
was specifically from an inpatient surgical ward. A high
percentage of the subjects had a PICC implanted for IV
parenteral nutrition: 84% for the Bard group and 74% for the
Cook group.
Both the Cook Turbo-Ject and the Bard PowerPicc Solo2
PICCs provide safe and effective venous access for a variety
328 B. Alport et al. / Canadian Association of Radiologists Journal 63 (2012) 323e328of clinical indications. Neither of the PICCs studied
demonstrated a statistically significant complication profile.
Nursing difficulties with one of the PICCS were perceived
but were not statistically validated, despite the sense that one
of the PICCs in question was particularly problematic.
Complications encountered while using a PICC for therapy
will vary considerably based upon PICC design, patient
disease, and the treatment location, to name a few possible
influential variables. These variables should be taken into
consideration when planning patient treatment.
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